Redeye comments on Cantargia's Q2 report. CAN10 is progressing according to plan with proof-of-mecha...
Redeye provides a more in-depth review of AcouSort’s Q2 report, which did not include any major surp...
STENOCARE A/S (“STENOCARE” or the “Company”) has executed on several strategically important milesto...
EcoRub (”EcoRub” eller ”bolaget”) publicerade den 28 augusti 2024 bolagets delårsrapport för det and...
Redeye expects the Integrum share to trade down considerably during the day.
Redeye comments on Maximum Entertainment’s Q2-results which saw softer topline than expected while a...
Media keeps delivering like clockwork, 18% organic growth in Q2 We remove Platform and Sportsbook fr...
Limited estimate revisions after solid Q2 with several promising signs Base machine is working, scal...
Redeye estimates an 85% probability of the Neonode side settling against Samsung in mid-2025, which ...
Redeye views favorably the announcement of the first order from the US Department of Veterans Affair...
Loihde’s Q2 was better than estimated, profitability in particular, with adj.
Embark Group AB (”Embark” eller ”Bolaget”) fortsatte under det andra kvartalet att kapitalisera på t...
Redeye returns with an update following Alzecure's Q2 report and recent activities in the company.
Q2 EBITDA 1% below cons on Sportsbook and Platform miss Decent start to Q3 with Media sales up 37% y...
First Venture Sweden (”First Venture” eller ”Bolaget”) är ett investmentbolag med fokus på snabbväxa...
Q2: 21% ARR growth in line, FCF of DKK -4m vs. ABGSCe DKK -6m Reiterates FY'24 guidance, as expected...
Active Biotechs samarbete i USA kring tasquinimod har påbörjat rekrytering till en fas 2-studie inom...
Recorded sales improved to SEK 16.7m (17.9m in Q1 and SEK 0m in Q2 2023), and the cash balance was ...
Redeye updates its view on Lifecare following the Q2 report and recent company developments, includi...
